[go: up one dir, main page]

SG11202005628RA - 4-azaindole compounds - Google Patents

4-azaindole compounds

Info

Publication number
SG11202005628RA
SG11202005628RA SG11202005628RA SG11202005628RA SG11202005628RA SG 11202005628R A SG11202005628R A SG 11202005628RA SG 11202005628R A SG11202005628R A SG 11202005628RA SG 11202005628R A SG11202005628R A SG 11202005628RA SG 11202005628R A SG11202005628R A SG 11202005628RA
Authority
SG
Singapore
Prior art keywords
azaindole compounds
azaindole
compounds
Prior art date
Application number
SG11202005628RA
Other languages
English (en)
Inventor
Alaric J Dyckman
Dharmpal S Dodd
Christopher P Mussari
Trevor C Sherwood
Brian K Whiteley
John L Gilmore
Sreekantha Ratna Kumar
Laxman Pasunoori
Pitani Veera Venkata Srinivas
Srinivasan Kunchithapatham Duraisamy
Subramanya Hegde
Rushith Kumar Anumula
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11202005628RA publication Critical patent/SG11202005628RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202005628RA 2017-12-18 2018-12-17 4-azaindole compounds SG11202005628RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762599875P 2017-12-18 2017-12-18
PCT/US2018/065908 WO2019125977A1 (fr) 2017-12-18 2018-12-17 Composés de 4-azaindole

Publications (1)

Publication Number Publication Date
SG11202005628RA true SG11202005628RA (en) 2020-07-29

Family

ID=65003548

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005628RA SG11202005628RA (en) 2017-12-18 2018-12-17 4-azaindole compounds

Country Status (28)

Country Link
US (4) US10544143B2 (fr)
EP (1) EP3728252B1 (fr)
JP (1) JP7289301B2 (fr)
KR (1) KR102720550B1 (fr)
CN (1) CN111819176B (fr)
AR (1) AR113959A1 (fr)
AU (1) AU2018388464B2 (fr)
BR (1) BR112020011771A2 (fr)
CA (1) CA3085817A1 (fr)
CL (1) CL2020001546A1 (fr)
DK (1) DK3728252T3 (fr)
EA (1) EA202091484A1 (fr)
ES (1) ES2960411T3 (fr)
FI (1) FI3728252T3 (fr)
HR (1) HRP20231244T1 (fr)
HU (1) HUE064473T2 (fr)
IL (1) IL275344B2 (fr)
LT (1) LT3728252T (fr)
MX (1) MX2020006168A (fr)
PE (1) PE20210129A1 (fr)
PL (1) PL3728252T3 (fr)
PT (1) PT3728252T (fr)
RS (1) RS64728B1 (fr)
SG (1) SG11202005628RA (fr)
SI (1) SI3728252T1 (fr)
SM (1) SMT202300342T1 (fr)
TW (1) TWI689510B (fr)
WO (1) WO2019125977A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
LT3728252T (lt) * 2017-12-18 2023-10-25 Bristol-Myers Squibb Company 4-azaindolo junginiai
MX2020006014A (es) * 2017-12-20 2020-08-17 Bristol Myers Squibb Co Compuestos de diazaindol.
ES2965182T3 (es) * 2017-12-20 2024-04-11 Bristol Myers Squibb Co Compuestos de indol sustituidos con arilo y heteroarilo
MX2020005513A (es) * 2017-12-20 2020-09-03 Bristol Myers Squibb Co Compuestos de amino indol utiles como inhibidores de receptores tipo toll (tlr).
EP3752505B1 (fr) 2018-02-12 2023-01-11 F. Hoffmann-La Roche AG Nouveaux composés et dérivés de sulfone pour le traitement et la prophylaxie d'une infection virale
BR112020024782A2 (pt) 2018-06-05 2021-03-02 F. Hoffmann-La Roche Ag compostos de tetra-hidro-1h-pirazino[2,1-a]isoindolilquinolina para o tratamento de doença autoimune
EP3807270B1 (fr) 2018-06-12 2023-09-13 F. Hoffmann-La Roche AG Nouveaux composés hétéroaryles hétérocyclyles pour le traitement d'une maladie auto-immune
WO2020020800A1 (fr) 2018-07-23 2020-01-30 F. Hoffmann-La Roche Ag Nouveaux composés de pipérazine pour le traitement d'une maladie auto-immune
US11639352B2 (en) 2018-09-04 2023-05-02 Hoffman-La Roche Inc. Benzothiazole compounds for the treatment of autoimmune diseases
EP3847173B1 (fr) 2018-09-06 2023-04-12 F. Hoffmann-La Roche AG Nouveaux composés de pyrazolopyridine pour le traitement d'une maladie auto-immune
WO2020048595A1 (fr) 2018-09-06 2020-03-12 F. Hoffmann-La Roche Ag Nouveaux composés amidine cyclique pour le traitement d'une maladie auto-immune
KR20220075381A (ko) 2019-10-01 2022-06-08 브리스톨-마이어스 스큅 컴퍼니 치환된 비시클릭 헤테로아릴 화합물
EP4038059B1 (fr) 2019-10-04 2023-09-20 Bristol-Myers Squibb Company Composés carbazole substitués
US12421240B2 (en) 2019-10-31 2025-09-23 Hoffmann-La Roche Inc. Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
CN114929345B (zh) * 2019-11-01 2024-07-23 百时美施贵宝公司 作为toll受体抑制剂的经取代的吡唑化合物
WO2021099284A1 (fr) 2019-11-19 2021-05-27 F. Hoffmann-La Roche Ag Composés d'hydro-1 h-pyrrolo[1,2-a]pyrazine pour le traitement d'une maladie auto-immune
CN114728988B (zh) 2019-11-20 2024-12-10 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的螺(异苯并呋喃氮杂环丁烷)化合物
CN115956077A (zh) * 2020-08-19 2023-04-11 百时美施贵宝公司 可做为tlr9抑制剂的经取代杂芳基化合物
CN116075510A (zh) 2020-08-19 2023-05-05 百时美施贵宝公司 1H-苯并[d]咪唑衍生物作为TLR9抑制剂用于治疗纤维化
AR123281A1 (es) * 2020-08-19 2022-11-16 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como inhibidores de tlr9
MX2023001929A (es) * 2020-08-19 2023-03-09 Bristol Myers Squibb Co Derivados de 1h-pirrol[3,2-c]piridina y 1h-pirrol[2,3-c]piridina como inhibidores del receptor tipo troll 9 (tlr9) para el tratamiento de fibrosis.
CA3200155A1 (fr) * 2020-11-26 2022-06-02 Xiaomin Zhang Compose tryciclique fusionne, son procede de preparation et son utilisation en medecine
CN116783202A (zh) * 2021-02-09 2023-09-19 吉利德科学公司 噻吩并吡咯化合物
JP2024513945A (ja) 2021-04-16 2024-03-27 ギリアード サイエンシーズ， インコーポレイテッド チオノピロール化合物
CN117957234A (zh) 2021-09-10 2024-04-30 吉利德科学公司 噻吩并吡咯化合物
CN114591339B (zh) * 2022-05-10 2022-08-02 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用
CR20250419A (es) 2023-04-06 2025-10-07 Pfizer Compuestos de derivados de ácido indazol propiónico sustituidos y usos de estos

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100348A3 (en) 1997-10-20 2002-12-28 Hoffmann La Roche Bicycles containing a six menbered ring with one or two nitrogen atoms, process for their preparation, use of them, pharmaceutical compositions containing the same and intermediates
CZ20012006A3 (cs) 1998-12-18 2002-03-13 Axys Pharmaceuticals, Inc. Sloučenina a farmaceutický prostředek
BRPI0411514A (pt) 2003-06-20 2006-08-01 Coley Pharm Gmbh antagonistas de receptor toll-like de molécula pequena
CA2564953A1 (fr) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Nouveaux derives d'indole agissant comme modulateurs de recepteurs androgenes selectifs (sarm)
US20060235037A1 (en) 2005-04-15 2006-10-19 Purandare Ashok V Heterocyclic inhibitors of protein arginine methyl transferases
US20090099179A1 (en) 2006-04-04 2009-04-16 Myriad Genetics, Incorporated Compounds for diseases and disorders
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
US7977352B2 (en) 2006-12-01 2011-07-12 Galapagos Nv Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
GB0708141D0 (en) 2007-04-26 2007-06-06 Syngenta Participations Ag Improvements in or relating to organic compounds
WO2008152471A1 (fr) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Antagoniste des récepteurs de type toll et ses utilisations
WO2009030996A1 (fr) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Composés triazole utilisés comme agonistes du récepteur de type toll (tlr)
CL2009000904A1 (es) * 2008-04-21 2010-04-30 Shionogi & Co Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
JP5788316B2 (ja) * 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
EP2350032B1 (fr) 2008-09-26 2016-05-25 Eisai R&D Management Co., Ltd. Composés benzoxazole et procédés d'utilisation
EP2340243B1 (fr) 2008-10-17 2014-10-08 Boehringer Ingelheim International GmbH Composés indole à substitution hétéroaryle utilisés comme inhibiteurs de mmp-13
EA021377B9 (ru) 2008-12-09 2015-09-30 Джилид Сайэнс, Инк. Модуляторы толл-подобных рецепторов
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
US20110015219A1 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof
WO2012054862A2 (fr) 2010-10-21 2012-04-26 The Brigham And Women's Hospital, Inc. Agents, compositions et méthodes pour traiter le prurit et des troubles dermiques associés
PL2663550T3 (pl) 2011-01-12 2017-07-31 Ventirx Pharmaceuticals, Inc. Podstawione benzoazepiny jako modulatory receptora toll-podobnego
HUE032638T2 (en) 2011-01-12 2017-10-30 Ventirx Pharmaceuticals Inc Toll receptor modulator substituted benzoazepines
KR102052215B1 (ko) 2011-06-01 2019-12-04 야누스 바이오테라퓨틱스, 인크. 신규한 면역 시스템 조절제
AU2012262021B2 (en) 2011-06-01 2016-07-28 Janus Biotherapeutics, Inc. Novel immune system modulators
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
ES2555167T3 (es) 2011-07-15 2015-12-29 Janssen Pharmaceuticals, Inc. Nuevos derivados de indol sustituidos como moduladores de gamma secretasa
JP2013075834A (ja) 2011-09-29 2013-04-25 Kowa Co Ｔｌｒ９阻害活性を有するピラゾロピリミジン−７−アミン誘導体
EP2763677B1 (fr) 2011-10-04 2020-02-26 Janus Biotherapeutics, Inc. Nouveaux modulateurs du système immunitaire à base d'imidazole quinoline
RU2636146C2 (ru) 2012-05-18 2017-11-21 Сумитомо Дайниппон Фарма Ко., Лтд. Соединения карбоновых кислот
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
EP2738172A1 (fr) * 2012-11-28 2014-06-04 Almirall, S.A. Nouveaux composés bicycliques utilisés comme modulateurs du canal crac
MY192489A (en) 2013-10-14 2022-08-23 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
US9643967B2 (en) 2013-12-13 2017-05-09 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors
MX386981B (es) 2014-08-15 2025-03-19 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
WO2016029077A1 (fr) 2014-08-22 2016-02-25 Janus Biotherapeutics, Inc. Nouveaux composés de ptéridine-2,4,7-triamine n2, n4, n7, 6-tétrasubstitués et de ptéridine 2, 4, 6, 7-tétrasubstitués, leurs procédés de synthèse et utilisation
AR103232A1 (es) 2014-12-22 2017-04-26 Bristol Myers Squibb Co ANTAGONISTAS DE TGFbR
KR102506321B1 (ko) * 2016-07-30 2023-03-03 브리스톨-마이어스 스큅 컴퍼니 Tlr7, tlr8 또는 tlr9 억제제로서의 디메톡시페닐 치환된 인돌 화합물
WO2018049089A1 (fr) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Composés indole substitués par pyridyle
LT3728252T (lt) * 2017-12-18 2023-10-25 Bristol-Myers Squibb Company 4-azaindolo junginiai

Also Published As

Publication number Publication date
AR113959A1 (es) 2020-07-01
KR20200100709A (ko) 2020-08-26
CN111819176A (zh) 2020-10-23
RS64728B1 (sr) 2023-11-30
EP3728252A1 (fr) 2020-10-28
IL275344A (en) 2020-07-30
TWI689510B (zh) 2020-04-01
IL275344B1 (en) 2023-04-01
US11053244B1 (en) 2021-07-06
KR102720550B1 (ko) 2024-10-21
US10730877B2 (en) 2020-08-04
EP3728252B1 (fr) 2023-08-09
ES2960411T3 (es) 2024-03-04
US20190185469A1 (en) 2019-06-20
JP2021506858A (ja) 2021-02-22
US20200095247A1 (en) 2020-03-26
US20220340555A1 (en) 2022-10-27
WO2019125977A1 (fr) 2019-06-27
US10544143B2 (en) 2020-01-28
PE20210129A1 (es) 2021-01-19
FI3728252T3 (fi) 2023-10-18
SI3728252T1 (sl) 2023-11-30
AU2018388464A1 (en) 2020-07-30
HUE064473T2 (hu) 2024-03-28
EA202091484A1 (ru) 2021-03-25
CN111819176B (zh) 2023-12-15
BR112020011771A2 (pt) 2020-11-17
AU2018388464B2 (en) 2022-07-21
US11820768B2 (en) 2023-11-21
HRP20231244T1 (hr) 2024-02-16
TW201927780A (zh) 2019-07-16
SMT202300342T1 (it) 2023-11-13
LT3728252T (lt) 2023-10-25
IL275344B2 (en) 2023-08-01
MX2020006168A (es) 2020-08-13
PL3728252T3 (pl) 2023-10-23
CL2020001546A1 (es) 2020-10-23
PT3728252T (pt) 2023-10-26
JP7289301B2 (ja) 2023-06-09
DK3728252T3 (da) 2023-11-13
CA3085817A1 (fr) 2019-06-27

Similar Documents

Publication Publication Date Title
IL275344A (en) 4-azaindole compounds
IL275365A (en) 6-Azaindole compounds
GB201708456D0 (en) Senolytic compounds
GB201700814D0 (en) Compounds
GB201704327D0 (en) Compounds
GB201715342D0 (en) Compounds
GB201704325D0 (en) Compounds
GB201713962D0 (en) Compounds
GB201707938D0 (en) Compounds
GB201707856D0 (en) Compounds
GB201706162D0 (en) Compounds
GB201702221D0 (en) Compounds
GB201716369D0 (en) Compounds
GB201715786D0 (en) Compounds
GB201707852D0 (en) Compounds
GB201703282D0 (en) Compounds
HK40037148A (en) 4-azaindole compounds
GB201716352D0 (en) Compounds
GB201716374D0 (en) Compounds
GB201713318D0 (en) Compounds
GB201713319D0 (en) Compounds
GB201711982D0 (en) Compounds
GB201709642D0 (en) Compounds
GB201708845D0 (en) Compounds
GB201708846D0 (en) Compounds